MARK KANZAWA: Open Payments
NPI 1982617288 · FLINT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$524 in 25 payments from 8 companies in 2025. Trend: 2023 $175 · 2024 $268 · 2025 $524
Food & beverage: $524
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 11 | $227 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Alkermes, Inc. | 3 | $66 |
| Neurocrine BioSciences, Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: COBENFY, CAPLYTA, INGREZZA, ARISTADA, FANAPT, LYBALVI, UZEDY, ABILIFY MAINTENA.
Industry payments across MI — which companies pay providers there.
